Key words: -r-aminobutyric acid -benzodiazepine receptors -basal ganglia -opiate receptors GABA and its associated benzodiazepine interactions play an important role in basal ganglia function. Distinctive GABA, benzodiazepine and opiate receptor changes occur in response to striatal lesions and in the human neurodegenerative disorder, Huntington's disease (HD). In animal experiments, the in vivo administration of [3H]flunitrazepam labels benzodiazepine receptors and can demonstrate the receptor changes seen after striatal lesions. It should be possible to measure these receptors in vivo in humans using positron-emission tomographic scanning.
The role of GABA in basal ganglia function. As in the rest of the nervous system, GABA has been found to play an important role in basal ganglia function [5, 9, 11, 13, 14, 20] . The caudate nucleus and putamen have high levels of GABA and glutamic acid decarboxylase (GAD) activity as do the lateral and medial globus pallidus and the substantia nigra pars reticulata [5, 14, 17] . The caudate nucleus and putamen receive excitatory input from all regions of the cerebral cortex and from the parafascicular nuclei of thalamus [5, 14] . They receive inhibitory input from the substantia nigra pars compacta and the raphe nuclei. The outputs of caudate nucleus and putamen go to the lateral and medial globus pallidus (LGP and MGP) and also to the pars reticulata of substantia nigra (SNr). The MGP and SNr project to ventral medial thalamus, which in turn projects to cerebral cortex.
A large proportion of striatal output cells are medium-sized spiny neurons which contain GAD-like immunoreactivity [17] . They have extensive local axon collaterals and send output to LGP, MGP and SNr [5, 9, 14] . These GABA neurons make direct connections with LGP, MGP and SNr neurons which also contain GABA [10, 14] . The GABAergic neurons in LGP project to subthalamic nucleus and those in MGP and SNr project to thalamus.
There are many other transmitters and neuromodulators in caudate-putamen in addition to GABA [5] . Only two important classes of modulators, the opiate peptides and the benzodiazepines, will be discussed here. The benzodiazepines interact with specific receptors in brain which are physiologically, pharmacologically and biochemically related to GABA receptors [7, 8] . Most evidence would suggest that the benzodiazepines interact with a subunit of the GABA receptor-chloride ionophore receptor complex [7, 8] . Leu-enkephalin, Met-enkephalin and dynorphin are all opiate peptides that are present in the caudate-putamen and at least some of these peptides appear to coexist in GABA neurons [4, 5, 9, 10] . These peptides may control the release of GABA or modify the action of GABA on the postsynaptic neurons. The presence of opiate peptides in the GABAergic striatal neurons distinguishes these GABA cells from those in MGP and SNr which do not contain opiate peptides [9] . Further work is needed before the role of these peptides in striatal function is defined.
The GABAergic output neurons of the caudate-putamen make synapses on GABAergic MGP/SNr cells [10] . Neurophysiologically, the MGP and SNr neurons are spontaneously active and the caudate-putamen output inhibits their activity [14] . The caudate-putamen is therefore in a position to function as a disinhibitor of the thalamus [14, 18] . Disinhibition of the thalamus is one mechanism by which the caudate-putamen may function to facilitate a particular behavior and surround-inhibit conflicting behaviors via local axon collaterals [14] . Diseases of the basal ganglia cause a disruption of this function. Parkinson's disease, which causes a slowness of movement, tremor and rigidity, results from loss of dopaminergic inhibitory input to caudate-putamen and therefore an over-activity of caudateputamen GABAergic inhibitory output to MGP and SNr. Patients with Parkinson's disease appear to have excessive reinforcement of ongoing behaviors and difficulty stopping one motor behavior to initiate a new one. Interestingly, atypical parkinsonism is frequently caused by pathology directly in the MGP and SNr, thereby directly disrupting GABAergic MGP and SNr output to thalamus [14] .
Huntington's disease (HD), often thought of as the clinical opposite of Parkinson's disease, is characterized by excessive motor activity, loss of motor persistence and difficulty carrying out coordinated motor tasks. In this disease, the caudateputamen shows profound neuronal loss and the MGP and SNr are deafferented [14, 19] . Unwanted behaviors are no longer suppressed and ongoing ones are not facilitated via disinhibition of the thalamus resulting in a breakdown of coordination and an excess of random movements.
Receptors in Hungtinton's disease and rats with striatal kainate lesions. We have investigated neurotransmitter receptors in animal models of Huntington's disease and postmortem tissues of patients dying with Huntington's disease. Although investigators have studied receptors in these preparations using homogenate techniques, only limited attention has been paid to striatal projection areas and to quantitative measurements in each sample [4, 16, 20] . We have focused on quantitative autoradiographic measurements of GABA, benzodiazepine and opiate receptors in these preparations to see whether the drug receptor changes are characteristic of the particular disease.
Using the kainic acid model of Huntington's disease in rats [3], we have examined receptors both acutely and chronically after lesions of the striatum. Acutely (1 week) after striatal kainate lesions, GABA receptors, as measured by [3H]muscimol binding, decrease locally in striatum but increase in globus pallidus (GP) (the murine counterpart of LGP), entopeduncular nucleus (EPN) (the murine counterpart of MGP) and SNr [11] . Benzodiazepine receptors decrease locally in striatum at 1 week but show no change in the striatal projection areas [12] . (Table I ). The results suggest that destruction of striatal neurons leads to local receptor loss because of the loss of neuronal cell bodies and axon collaterals. In striatal projection areas, GABA and benzodiazepine receptors increase on the postsynaptic neurons in response to deafferentation, and opiate receptors decrease presumably because of their location on the striatal presynaptic terminals (Fig. 1) . No changes in receptor affinity for any of the ligands were seen in any region [1, 11, 12] . Fig. 1 . Schematic of GABAergic connections in basal ganglia. GABA (plus opiate) neurons in caudateputamen send inhibitory projections to MGP/SNr. The MGP/SNr neurons are GABAergic in turn and project to ventral medial thalamus. Opiate receptors (e) appear to be located presynaptically on caudate-putamen neurons and nerve terminals and therefore decrease in both caudate-putamen and MGP/SNr after striatal lesions. GABA and benzodiazepine receptors (A) are located postsynaptically on caudate-putamen and MGP/SNr neurons and decrease locally but increase in MGP/SNr after striatal lesions.
The same autoradiographic methods used in the animal studies were applied to the investigation of receptors in postmortem tissues of controls and patients dying of Huntington's disease (Table II) . Virtually identical changes were seen in the human material as in the chronic animal preparations [13, 15, 21] . Thus GABA and benzodiazepine receptors decrease in striatum and increase in globus pallidus, and opiate receptors decrease in both striatum and globus pallidus. The receptor changes appear to occur early in Huntington's disease as evidenced by the observation of decreased striatal and increased pallidal GABA and benzodiazepine receptors in the brains of two Huntington's disease cases who died early in the disease. These brains showed no gross atrophy and only minimal neuronal cell loss in caudate-putamen at autopsy [21] .
In vivo imaging of receptor changes in rat. The distinctiveness of the drug receptor changes in Huntington's disease suggests that measurement of receptors in vivo might show changes early in the disease and, possibly, even presymptomatically.
With the recent discovery of a linkage marker in Huntington's disease [6] , it will be important to define objective measures of the earliest changes in brain so that potential therapies can be started prior to substantial brain damage. It would then be possible to assess prospectively the deterioration of brain function and the ability of therapies to retard or halt the progression of disease. 
